Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in four phase 3 odyssey trials with/without statin background. (September 2016) - Robinson, J.G.; Farnier, M.; Kastelein, J.J.; Roth, E.M.; Taskinen, M.R.; Colhoun, H.M.; Brunet, A.; DiCioccio, A.T.; Lecorps, G.; Pordy, R.; Baccara-Dinet, M.T.; Cannon, C.P.